Curiously, VRUS’ phase-1b trial runs for seven days, which is four days longer than the typical 3-day limit imposed by the FDA for US monotherapy studies in HCV patients.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”